Previous slide arrow

IMP Welcomes FDA Approval of First-Ever Treatment for TK2d

IMP is delighted to welcome the approval by the U.S. FDA of KYGEVVI® (doxecitine and doxribtimine) for the treatment of adults and children living with Thymidine Kinase 2 Deficiency (TK2d), with an age of symptom onset on or before 12 years.

Scientist hands holding chemical compound bathed in light

Thank You for Supporting Mito Week 2025

Your participation has helped shine a light on mitochondrial disease and strengthen the call for awareness, research, and support. Let’s keep raising awareness together and continue driving change beyond this week. We’re already looking forward to building on this momentum for next year’s campaign.

TK2D Awareness Day – 9 September 2025

Watch Lisa, Aneesa and Viviane tell their stories of living with K2d (thymidine kinase 2 deficiency), diagnosis, the heartbreak of loss, and the hope brought by clinical trials and community support.

Image of a mother with long blonde dreadlocks holding a child with short black hair on her lap who is attached to a breathing machine

LHON Awareness Day – 19 September 2025

Watch our webinar on nutrition and mitochondrial diseases with a special focus on LHON.

Title slide of a presentation showing the title 'Exploring the Power of Nutrition in Mitochondrial Diseases'
r


Mitochondrial diseases (mito) are a highly complex set of rare genetic disorders. Mito can cause any symptom in any organ at any age. They rob the body’s cells of energy causing debilitating and often life-threatening organ dysfunction.

About
MITO

NEWS

IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by […]...

Watch our Webinar: The power of nutrition and mitochondrial diseases

Watch our Webinar: The power of nutrition and mitochondrial diseases As part of LHON Awareness Day, we hosted a powerful […]...

From Advocacy to Access: Mito Community Celebrates FDA Milestone

Barth syndrome therapy sets precedent for future treatments targeting mitochondrial dysfunction In a landmark decision, the U.S. Food and Drug […]...

IMP Launches New TK2d Video

IMP Launches New TK2d Video To mark TK2d Awareness Day 2025, we’ve released a new video that amplifyies the voices […]...

IMP Welcomes Three New Members

IMP now has members across three continents We’re delighted to welcome three new members to IMP. With these new members, […]...

Meet
a member

The POLG Foundation

The PolG Foundation is committed to accelerating research efforts to develop effective treatments and, ultimately, a cure for POLG mitochondrial disorders.


Become
a member

Are you thinking of becoming an IMP member?

Patient Stories

Ellie was a fighter from birth. Born in October 2017, a lack of oxygen at birth meant she needed to spend the first week of life in intensive care. This early battle in life would later be a blessing in disguise as it meant she required regular neurological reviews to review how her brain and movement developed. Ellie’s early months were mainly happy. She cried, babbled and smiled like any baby does and loved baths with her big sister, kicking her legs to music and chatting away with her mum and dad.

About
IMP

International Mito Patients is a non-profit network of national patient organisations involved in mito. The national patient organisations support and advocate for patients, fund research, increase awareness and improve education in their country.

By joining forces, IMP represents a large group of patients, creating a stronger voice on an international level.

IMP’s mission is to increase the quality of life for people with mitochondrial disease by facilitating cross-border cooperation and collaboration among national patient organisations.


Stay up
to date

Translate
Scroll to Top
Skip to content